Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

314 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study.
Martín A, Conde E, Arnan M, Canales MA, Deben G, Sancho JM, Andreu R, Salar A, García-Sanchez P, Vázquez L, Nistal S, Requena MJ, Donato EM, González JA, León A, Ruiz C, Grande C, González-Barca E, Caballero MD; Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea (GEL/TAMO Cooperative Group). Martín A, et al. Among authors: conde e. Haematologica. 2008 Dec;93(12):1829-36. doi: 10.3324/haematol.13440. Epub 2008 Oct 22. Haematologica. 2008. PMID: 18945747 Free article.
Effect of addition of rituximab to salvage chemotherapy on outcome of patients with diffuse large B-cell lymphoma relapsing after an autologous stem-cell transplantation.
Calvo-Villas JM, Martín A, Conde E, Pascual A, Heras I, Varela R, de la Rubia J, Ramirez MJ, Díez-Martín JL, Panizo C, Rodríguez-Salazar MJ, Pascual MJ, Donato EM, González-Barca E, Caballero MD; Grupo Español de Linfomas/Trasplante Autólogo de Médula Ósea (GEL/TAMO cooperative group). Calvo-Villas JM, et al. Among authors: conde e. Ann Oncol. 2010 Sep;21(9):1891-1897. doi: 10.1093/annonc/mdq035. Epub 2010 Mar 15. Ann Oncol. 2010. PMID: 20231299 Free article.
High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience.
Rodriguez J, Caballero MD, Gutierrez A, Gandarillas M, Sierra J, Lopez-Guillermo A, Sureda A, Zuazu J, Marin J, Arranz R, Carreras E, Leon A, De Sevilla AF, San Miguel JF, Conde E; GEL/TAMO Spanish Group. Rodriguez J, et al. Among authors: conde e. Haematologica. 2003 Dec;88(12):1372-7. Haematologica. 2003. PMID: 14687990 Free article.
First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from the GELTAMO group.
Arranz R, García-Noblejas A, Grande C, Cannata-Ortiz J, Sánchez JJ, García-Marco JA, Aláez C, Pérez-Calvo J, Martínez-Sánchez P, Sánchez-González B, Canales MA, Conde E, Martín A, Arranz E, Terol MJ, Salar A, Caballero D. Arranz R, et al. Among authors: conde e. Haematologica. 2013 Oct;98(10):1563-70. doi: 10.3324/haematol.2013.088377. Epub 2013 Jun 10. Haematologica. 2013. PMID: 23753021 Free PMC article. Clinical Trial.
Impact of prior rituximab on outcomes of autologous stem-cell transplantation in patients with relapsed or refractory aggressive B-cell lymphoma: a multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study.
Redondo AM, Pomares H, Vidal MJ, Pascual MJ, Quereda B, Sancho JM, Polo M, López J, Conde E, Jarque I, Alonso N, Ramírez MJ, Fernández P, Sayas MJ, Requena MJ, Salar A, González JD, González-Barca E, Arranz R, Caballero D, Martín A. Redondo AM, et al. Among authors: conde e. Br J Haematol. 2014 Mar;164(5):668-74. doi: 10.1111/bjh.12676. Epub 2013 Nov 26. Br J Haematol. 2014. PMID: 24274082 Free article.
Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial.
Pardal E, Coronado M, Martín A, Grande C, Marín-Niebla A, Panizo C, Bello JL, Conde E, Hernández MT, Arranz R, Bargay J, González-Barca E, Pérez-Ceballos E, Montes-Moreno S, Caballero MD. Pardal E, et al. Among authors: conde e. Br J Haematol. 2014 Nov;167(3):327-36. doi: 10.1111/bjh.13036. Epub 2014 Jul 28. Br J Haematol. 2014. PMID: 25066542 Free article. Clinical Trial.
The adjusted International Prognostic Index and beta-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma.
Rodríguez J, Conde E, Gutiérrez A, Lahuerta JJ, Arranz R, Sureda A, Zuazu J, Fernández de Sevilla A, Bendandi M, Solano C, León A, Varela MR, Caballero MD; Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea, Spanish Lymphoma/Autologous Bone Marrow Transplant Study Group. Rodríguez J, et al. Among authors: conde e. Haematologica. 2007 Aug;92(8):1067-74. doi: 10.3324/haematol.11173. Epub 2007 Jul 20. Haematologica. 2007. PMID: 17640855 Free article.
Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group.
Arranz R, Conde E, Grande C, Mateos MV, Gandarillas M, Albo C, Lahuerta JJ, Fernández-Rañada JM, Hernández MT, Alonso N, García Vela JA, Garzón S, Rodríguez J, Caballero D; Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea (GEL-TAMO). Arranz R, et al. Among authors: conde e. Eur J Haematol. 2008 Mar;80(3):227-35. doi: 10.1111/j.1600-0609.2007.01020.x. Epub 2007 Dec 18. Eur J Haematol. 2008. PMID: 18088400 Clinical Trial.
Risk adapted high-dose and dose-dense therapies modulate the impact of biological classification in diffuse large B-cell lymphoma prognosis.
Montes-Moreno S, Batlle A, de Villambrosía SG, Sánchez-Espiridión B, Cereceda L, González-Barca E, Purroy N, Pardal E, Martín A, Grande C, Mazorra F, Insunza A, Quero C, Aguiar D, Cruz MA, Rueda A, Llanos M, Codina JG, Arroyo FR, Caballero D, Conde E, López A, Provencio M, Piris M. Montes-Moreno S, et al. Among authors: conde e. Haematologica. 2014 Aug;99(8):e138-41. doi: 10.3324/haematol.2014.104976. Epub 2014 Apr 24. Haematologica. 2014. PMID: 24763400 Free PMC article. Clinical Trial. No abstract available.
Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial.
Cabrero M, Martin A, Briones J, Gayoso J, Jarque I, López J, Grande C, Heras I, Arranz R, Bernal T, Perez-Lopez E, López-Godino O, Conde E, Caballero D. Cabrero M, et al. Among authors: conde e. Biol Blood Marrow Transplant. 2017 Jan;23(1):53-59. doi: 10.1016/j.bbmt.2016.10.003. Epub 2016 Oct 19. Biol Blood Marrow Transplant. 2017. PMID: 27771496 Free article. Clinical Trial.
314 results